盐酸坦索罗辛治疗良性前列腺增生症的临床疗效评估

Tamsulosin for the treatment of benign prostatic hyperplasia

为了评估α１Ａ受体阻断剂盐酸坦索罗辛对良性前列腺增生症（ＢＰＨ）的疗效和安全性，从１９９７年７月至１０月对６０例症状性ＢＰＨ给予盐酸坦索罗辛０．２ｍｇ口服，每天一次，治疗观察６周。结果表明病人主观症状明显改善，Ⅰ－ＰＳＳ评分降低３９．７％；最大尿流率（ＭＦＲ）和平均尿流率（ＡＦＲ）分别提高２２．９％、３６％。盐酸坦索罗辛对所有病人前列腺体积、血压、脉搏无明显影响（Ｐ＞０．０５），其中４７例残余尿（ＰＶＲ）下降５１．６％（Ｐ＜０．０１）。副反应较轻。

To investigate the efficacy and safety of Tamsulosin for benign prostatic hyperplasia (BPH), from July 1997 to Oct. 1997, 60 patients with symptomatic BPH were received tamsulosin 0.2mg daily for 6 weeks. The results showed that patients had a clinically significant response to the treatment of tamsulosin, and defined as those with 39.7% decrease in Ⅰ-PSS scores; 22.9% and 36% improvement in maximal urinary flow rate (MFR) and average urinary flow rate (AFR), respectively. Post-void residual urine (PVR) decreased in 51.6% ( P <0.01) in 47 patients. Tamsulosin had no significant effect on prostatic volume, blood pressure and pulse rate for all of the patients ( P >0.05 respectively). Mild adverse effects were noticed.